Rosenblatt, Tatiana R.
Ji, Marco H.
Vail, Daniel
Ludwig, Cassie A.
Al-Moujahed, Ahmad
Pasricha, Malini Veerappan
Callaway, Natalia F.
Kumm, Jochen
Moshfeghi, Darius M.
Funding for this research was provided by:
Heed Fellowship awarded through the Society of Heed Fellows to Cassie A. Ludwig, MD, MS
Article History
Received: 7 November 2020
Accepted: 15 February 2021
First Online: 8 March 2021
Competing interests
: T.R. Rosenblatt, None; M.H. Ji, None; D. Vail, None; C.A. Ludwig, None; A. Al-Moujahed, None; M. Veerappan Pasricha, None; N.F. Callaway, None; J. Kumm, Pr3vent INC (F,CEO); D.M. Moshfeghi, 1-800Contacts (BOD,E), Akceso Advisors AG (C), Akebia (SAB), Alcon (C), Aldeyra Therapeutics (PI), Alexion (C), Allegro (SAB), Apellis (PI), Bayer Pharma AG (SC,C), CMEOutfitters.com (C), Congruence Medical Solutions (C), dSentz, Inc. (F,E,BOD), Grand Legend Technology, LTD (E), Iconic Therapeutics (SC), Irenix (SAB), Linc (F,E,BOD), M3 Global Research (C), Northwell Health (C), Novartis Pharmaceuticals (DMC, C), Ocular Surgery News (C), Pr3vent INC (F,E,BOD), Praxis UNS, Inc. (C), Prime Medical Education (C), Promisight, Inc (F, E, BOD), Pykus (E,SAB), Regeneron (SC,PI), Retina Technologies LLC (SAB,C,E), Retina Today/Pentavision (C), Shapiro Law Group (C), SLACK, Inc (C), Versl, Inc. (F E), Vindico (C), Visunex (E,SAB).